GTC
CRSP icon

Ghost Tree Capital’s CRISPR Therapeutics CRSP Stock Holding History

Ghost Tree Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150,000
Closed -$3.52M – 55
2017
Q4 		$3.52M Buy
+150,000
New +$2.85M 0.83% 36

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Ghost Tree Capital's CRSP Position: Q1 2018 in Review

Ghost Tree Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2018, closing a stake of 150,000 shares — an estimated $3.52M sold.

Ghost Tree Capital first reported a position in CRSP in Q4 2017 and held it in 1 quarter. The position peaked at $3.52M in Q4 2017. 135 funds tracked by Wall St. Rank hold CRSP as of Q1 2018.

  • Ghost Tree Capital reported no remaining CRISPR Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ghost Tree Capital sold 150,000 CRISPR Therapeutics shares in Q1 2018, an estimated $3.52M.
  • Ghost Tree Capital first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 1 quarter.
  • Ghost Tree Capital's CRISPR Therapeutics position peaked at $3.52M in Q4 2017.
  • 135 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2018.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.